AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:AGENAgenus Stock Price, Forecast & News

$2.88
+0.13 (+4.73 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.74
Now: $2.88
$2.94
50-Day Range
$2.29
MA: $2.58
$2.83
52-Week Range
$1.82
Now: $2.88
$4.57
Volume4.14 million shs
Average Volume2.30 million shs
Market Capitalization$482.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More
Agenus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.05 million
Book Value($1.21) per share

Profitability

Net Income$-107,660,000.00
Net Margins-204.33%

Miscellaneous

Employees294
Market Cap$482.07 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Agenus (NASDAQ:AGEN) Frequently Asked Questions

How has Agenus' stock been impacted by COVID-19 (Coronavirus)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGEN shares have increased by 5.9% and is now trading at $2.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Agenus.

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02. The biotechnology company earned $15.13 million during the quarter, compared to the consensus estimate of $12.35 million. View Agenus' earnings history.

What price target have analysts set for AGEN?

1 brokerages have issued 1-year target prices for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View analysts' price targets for Agenus.

Has Agenus been receiving favorable news coverage?

News stories about AGEN stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Agenus earned a news impact score of -3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAgenus.

Are investors shorting Agenus?

Agenus saw a increase in short interest in April. As of April 15th, there was short interest totaling 15,210,000 shares, an increase of 8.7% from the March 31st total of 13,990,000 shares. Based on an average daily volume of 2,400,000 shares, the days-to-cover ratio is presently 6.3 days. Currently, 11.7% of the shares of the stock are short sold. View Agenus' Current Options Chain.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
  • Dr. Jennifer Buell, Chief Operating Officer
  • Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
  • Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
  • Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (7.27%), BlackRock Inc. (6.13%), Oracle Investment Management Inc. (3.20%), State Street Corp (2.31%), Geode Capital Management LLC (0.93%) and Wells Fargo & Company MN (0.67%). View institutional ownership trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., State Street Corp, UBS Group AG, and Alps Advisors Inc.. View insider buying and selling activity for Agenus.

Which institutional investors are buying Agenus stock?

AGEN stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Oracle Investment Management Inc., Two Sigma Advisers LP, Cadence Capital Management LLC, Russell Investments Group Ltd., Nuveen Asset Management LLC, Wells Fargo & Company MN, and Trellus Management Company LLC. View insider buying and selling activity for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.88.

How big of a company is Agenus?

Agenus has a market capitalization of $482.07 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.